Wednesday, 20 August 2014

Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-analysis Taking into Account Biases and Confounders

Our results show that metformin may reduce cancer incidence and mortality in patients with diabetes However, the reduction seems to be of modest magnitude and not affecting all populations equally (Cancer Prevention Research)


Mitsubishi Tanabe and AstraZeneca announce research collaboration in diabetic nephropathy

The three-year research collaboration will develop small molecule candidates from their respective portfolios (Mitsubishi Tanabe)


U.S. FDA Approves INVOKAMET™ (canagliflozin/metformin HCl) for the Treatment of Adults with Type 2 Diabetes

INVOKAMET™ is the first fixed-dose combination of an SGLT2 inhibitor with metformin approved in the United States (Janssen)


Stress Hyperglycaemia in Hospitalised Patients and Their 3-Year Risk of Diabetes: A Scottish Retrospective Cohort Study

Plasma glucose measured during an emergency hospital admission predicts subsequent risk of developing type 2 diabetes (PLoS Medicine)

No comments:

Post a Comment